Shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) ended Friday session in red amid volatile trading. The shares closed down -0.16 points or -0.37% at $43.42 with 2.13 million shares getting traded. Post opening the session at $43.20, the shares hit an intraday low of $43.18 and an intraday high of $43.53 and the price vacillated in this range throughout the day. The company has a market cap of $105.87 billion and the numbers of outstanding shares have been calculated to be 4.87 billion shares.
GlaxoSmithKline plc (ADR) (GSK) on Sept. 14, 2016 announced the publication of detailed results from a randomised phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix™, showing 90% efficacy in adults aged 70 years and older that is maintained for at least four years. The results were published in the New England Journal of Medicine (NEJM).
The study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old. Vaccine efficacy was maintained across the various age groups included in the study, ranging between 90% in people aged 70-79 years (95% confidence interval: 83-94%) and 89% in those aged 80 years and above1(95% confidence interval: 74-96%).
The high efficacy is in line with the results of the ZOE-50 trial, a study in people over 50 years old which was presented and published last year showing a 97% efficacy (95% confidence interval: 93-99%). A pooled analysis of data from both trials showed the vaccine demonstrated 91% efficacy against shingles (95% confidence interval: 86-95%) in adults aged 70 years and older compared to placebo. This efficacy was maintained with an 88% reduction in the risk of shingles (95% confidence interval: 73-95%) in the fourth year after vaccination.
Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) ended Friday session in green amid volatile trading. The shares closed up +0.25 points or 10.20% at $2.70 with 1.99 million shares getting traded. Post opening the session at $2.55, the shares hit an intraday low of $2.55 and an intraday high of $2.82 and the price vacillated in this range throughout the day. The company has a market cap of $159.61 million and the numbers of outstanding shares have been calculated to be 53.59 million shares.
BioDelivery Sciences International, Inc. (BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2016 Healthcare Conference. The presentation, which will be webcast, is scheduled for Tuesday, September 27, at 8:30 AM Eastern Time at the Sofitel New York in New York City.
Dr. Sirgo will discuss strategic initiatives supporting BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and the launch of BELBUCA™ (buprenorphine) buccal film (CIII) by BDSI’s commercial partner, Endo Pharmaceuticals. Also covered will be an update on the development of Clonidine Topical Gel for painful diabetic neuropathy and the buprenorphine 30-day injection for opioid dependence and chronic pain.
The presentation will be webcast live and can be accessed at www.bdsi.com. For those who are not available to listen to the live broadcast, replay of the webcast will be available on the BDSI website.